Valuation: BioNxt Solutions Inc.

Market Cap 53.08M 38.08M 33M 31.19M 28.32M 3.65B 53.39M 372M 144M 1.85B 143M 140M 5.91B P/E 2024
-7.97x
P/E 2025 -10.8x
Enterprise Value 58.97M 42.31M 36.67M 34.66M 31.46M 4.06B 59.32M 414M 160M 2.06B 159M 155M 6.56B EV / Sales 2024
1,754x
EV / Sales 2025 -
Free-Float
94.6%
Yield 2024 *
-
Yield 2025 -
08-28 BioNxt Solutions Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-08 BioNxt Solutions Advances GLP-1 Sublingual Semaglutide Oral Dissolvable Film Program With Next Stage Of Delivery Development Underway CI
06-22 BioNxt Solutions Inc. announced that it has received CAD 2 million in funding CI
06-11 BioNxt Solutions Inc. announced that it expects to receive CAD 2 million in funding CI
05-29 BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-20 BioNxt Solutions Inc Signs Exclusive Negotiation Framework for Potential Commercialization of Cladribine Oral Thin Film Product in Eurasian Patent Organization Member States CI
05-20 BioNxt Solutions Inc Initiates GMP Manufacturing Of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis CI
05-20 BioNxt Solutions Inc. Evaluates Application of Proprietary Drug Delivery Technologies to Psychedelic Therapeutics CI
05-20 BioNxt Solutions Inc. Advances Semaglutide Oral Dissolvable Film Program into Active Pharmaceutical Development CI
05-20 Bionxt Solutions Inc Advances Semaglutide Oral Thin-Film Program and Glp-1 Odf Platform Strategy CI
05-20 BioNxt Solutions Inc. Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform CI
04-29 BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-28 BioNxt Solutions Inc. Auditor Raises 'Going Concern' Doubt CI
1 week+16.42%
Current month+13.04%
1 month+16.42%
3 months+2.63%
6 months-29.09%
Current year-39.06%
1 week 0.34
Extreme 0.34
0.39
1 month 0.3
Extreme 0.3
0.39
Current year 0.28
Extreme 0.28
0.69
1 year 0.28
Extreme 0.28
0.91
3 years 0
Extreme 0
1.1
5 years 0
Extreme 0
1.7
10 years 0
Extreme 0
3.55
Manager TitleAgeSince
Chief Executive Officer 45 2017-12-11
Chief Executive Officer 46 2017-12-11
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2017-12-11
Director/Board Member 60 2018-12-09
Director/Board Member 45 2017-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Option

Director

100,000 0.0769%
7/31/26 Option

Chief Financial Officer

100,000 0.0769%
7/31/26 Option

Founder

650,000 0.5000%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+16.42%-40.00%+16.42% 38.08M
+0.15%+1.21%+48.79%+97.65% 1,014B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 464B
+0.53%+4.26%+40.29%+38.70% 354B
+0.39%+2.35%+17.96%+23.87% 265B
+0.17%+4.17%+6.96%+10.93% 253B
+0.19%-3.81%+37.81%+44.35% 203B
-1.20%-5.64%-24.09%-59.10% 186B
+0.94%+1.39%+33.21%+95.16% 183B
Average +0.10%-0.84%+19.38%+40.61% 356.68B
Weighted average by Cap. +0.11%+0.32%+34.38%+59.76%

Financials

2024 2025
Net sales 26.98K 19.36K 16.78K 15.86K 14.4K 1.86M 27.15K 189K 73.16K 942K 72.74K 71.12K 3M -
Net income -5.31M -3.81M -3.3M -3.12M -2.83M -366M -5.34M -37.27M -14.4M -185M -14.32M -14M -591M -7.03M -5.04M -4.37M -4.13M -3.75M -484M -7.07M -49.29M -19.05M -245M -18.94M -18.52M -782M
Net Debt 4.25M 3.05M 2.64M 2.5M 2.27M 292M 4.27M 29.8M 11.52M 148M 11.45M 11.19M 473M 5.89M 4.23M 3.66M 3.46M 3.14M 406M 5.93M 41.34M 15.97M 206M 15.88M 15.53M 656M
Logo BioNxt Solutions Inc.
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
Employees
-
Date Price Change Volume
26-09-16 $0.3900 +14.71% 72,000
26-09-14 $0.3400 0.00% 500
26-09-11 $0.3400 +3.03% 20,230
26-09-10 $0.3300 -1.49% 98,921
26-09-09 $0.3350 -6.94% 36,500
  1. Stock Market
  2. Stocks
  3. BNXT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!